Cargando…
Reduced risk of severe COVID-19 in more than 1.4 million elderly people aged 75 years and older vaccinated with mRNA-based vaccines
Randomized clinical trials have shown mRNA-based vaccines to be 92–95% effective to prevent COVID-19 in adults. We aimed to estimate the impact of vaccination on the risk of severe COVID-19 (requiring hospitalization) in elderly people. Each 1,422,461 vaccinated subject aged 75 or older was matched...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664658/ https://www.ncbi.nlm.nih.gov/pubmed/34924220 http://dx.doi.org/10.1016/j.vaccine.2021.12.009 |
_version_ | 1784613888612892672 |
---|---|
author | Botton, Jérémie Dray-Spira, Rosemary Baricault, Bérangère Drouin, Jérôme Bertrand, Marion Jabagi, Marie-Joëlle Weill, Alain Zureik, Mahmoud |
author_facet | Botton, Jérémie Dray-Spira, Rosemary Baricault, Bérangère Drouin, Jérôme Bertrand, Marion Jabagi, Marie-Joëlle Weill, Alain Zureik, Mahmoud |
author_sort | Botton, Jérémie |
collection | PubMed |
description | Randomized clinical trials have shown mRNA-based vaccines to be 92–95% effective to prevent COVID-19 in adults. We aimed to estimate the impact of vaccination on the risk of severe COVID-19 (requiring hospitalization) in elderly people. Each 1,422,461 vaccinated subject aged 75 or older was matched to two unvaccinated subjects of same age, sex, administrative region, and type of residence. They were followed from date of first injection between 27 December 2020 and 24 February 2021 to 20 March 2021 for COVID-19 hospitalization. Mean age was 82.4 years (SD, 5.7) and median follow-up was 38 days [IQR, 17–54]. Adjusted Hazard Ratio for COVID-19 hospitalization from day 7 after the second dose was estimated at 0.14 (95% confidence interval, 0.11–0.17), i.e. an estimated 86% risk reduction in people aged 75 and older, highlighting the major impact of mRNA vaccination on reducing the risk of COVID-19 among elderly people. |
format | Online Article Text |
id | pubmed-8664658 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86646582021-12-14 Reduced risk of severe COVID-19 in more than 1.4 million elderly people aged 75 years and older vaccinated with mRNA-based vaccines Botton, Jérémie Dray-Spira, Rosemary Baricault, Bérangère Drouin, Jérôme Bertrand, Marion Jabagi, Marie-Joëlle Weill, Alain Zureik, Mahmoud Vaccine Short Communication Randomized clinical trials have shown mRNA-based vaccines to be 92–95% effective to prevent COVID-19 in adults. We aimed to estimate the impact of vaccination on the risk of severe COVID-19 (requiring hospitalization) in elderly people. Each 1,422,461 vaccinated subject aged 75 or older was matched to two unvaccinated subjects of same age, sex, administrative region, and type of residence. They were followed from date of first injection between 27 December 2020 and 24 February 2021 to 20 March 2021 for COVID-19 hospitalization. Mean age was 82.4 years (SD, 5.7) and median follow-up was 38 days [IQR, 17–54]. Adjusted Hazard Ratio for COVID-19 hospitalization from day 7 after the second dose was estimated at 0.14 (95% confidence interval, 0.11–0.17), i.e. an estimated 86% risk reduction in people aged 75 and older, highlighting the major impact of mRNA vaccination on reducing the risk of COVID-19 among elderly people. Published by Elsevier Ltd. 2022-01-24 2021-12-11 /pmc/articles/PMC8664658/ /pubmed/34924220 http://dx.doi.org/10.1016/j.vaccine.2021.12.009 Text en © 2021 Published by Elsevier Ltd. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Short Communication Botton, Jérémie Dray-Spira, Rosemary Baricault, Bérangère Drouin, Jérôme Bertrand, Marion Jabagi, Marie-Joëlle Weill, Alain Zureik, Mahmoud Reduced risk of severe COVID-19 in more than 1.4 million elderly people aged 75 years and older vaccinated with mRNA-based vaccines |
title | Reduced risk of severe COVID-19 in more than 1.4 million elderly people aged 75 years and older vaccinated with mRNA-based vaccines |
title_full | Reduced risk of severe COVID-19 in more than 1.4 million elderly people aged 75 years and older vaccinated with mRNA-based vaccines |
title_fullStr | Reduced risk of severe COVID-19 in more than 1.4 million elderly people aged 75 years and older vaccinated with mRNA-based vaccines |
title_full_unstemmed | Reduced risk of severe COVID-19 in more than 1.4 million elderly people aged 75 years and older vaccinated with mRNA-based vaccines |
title_short | Reduced risk of severe COVID-19 in more than 1.4 million elderly people aged 75 years and older vaccinated with mRNA-based vaccines |
title_sort | reduced risk of severe covid-19 in more than 1.4 million elderly people aged 75 years and older vaccinated with mrna-based vaccines |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664658/ https://www.ncbi.nlm.nih.gov/pubmed/34924220 http://dx.doi.org/10.1016/j.vaccine.2021.12.009 |
work_keys_str_mv | AT bottonjeremie reducedriskofseverecovid19inmorethan14millionelderlypeopleaged75yearsandoldervaccinatedwithmrnabasedvaccines AT drayspirarosemary reducedriskofseverecovid19inmorethan14millionelderlypeopleaged75yearsandoldervaccinatedwithmrnabasedvaccines AT baricaultberangere reducedriskofseverecovid19inmorethan14millionelderlypeopleaged75yearsandoldervaccinatedwithmrnabasedvaccines AT drouinjerome reducedriskofseverecovid19inmorethan14millionelderlypeopleaged75yearsandoldervaccinatedwithmrnabasedvaccines AT bertrandmarion reducedriskofseverecovid19inmorethan14millionelderlypeopleaged75yearsandoldervaccinatedwithmrnabasedvaccines AT jabagimariejoelle reducedriskofseverecovid19inmorethan14millionelderlypeopleaged75yearsandoldervaccinatedwithmrnabasedvaccines AT weillalain reducedriskofseverecovid19inmorethan14millionelderlypeopleaged75yearsandoldervaccinatedwithmrnabasedvaccines AT zureikmahmoud reducedriskofseverecovid19inmorethan14millionelderlypeopleaged75yearsandoldervaccinatedwithmrnabasedvaccines |